Drug intelligence / Profile preview

TZ-113

Development stage: Unknown
Lead developer: TechnoPhage
Modality: Small Molecules

Overview

TZ-113 is a small molecule drug candidate developed by TechnoPhage SA. It is currently in the discovery phase and is being investigated primarily for the treatment of Parkinson's disease, specifically targeting levodopa-induced complications in Parkinson's patients. The drug falls under therapeutic areas related to nervous system diseases and endocrinology/metabolic diseases. As of the latest update, no detailed mechanism of action or molecular target has been disclosed publicly[1][3].

Beyond the preview

Go deeper on TZ-113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TZ-113.

Explore the full profile